Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 85-92 , March 2009

Heparanase coagulation and cancer progression

  • Yona Nadir, MD, PhD (Doctor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +972 4 8453520; Fax: +972 4 8543886.
    • ,
  • Benjamin Brenner, MD (Professor)

References 

  1. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004;50:187–196
  2. Haim N, Lanir N, Hoffman R, et al. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med. 2001;110:91–96
  3. Rao LV, Pendurthi UR. Tissue factor–factor VIIa signaling. Arterioscler Thromb Vasc Biol. 2005;25:47–56
  4. Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost. 2006;32:24–32
  5. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol. 2002;22:539–548
  6. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 2006;208:327–339
  7. Freeman C, Parish CR. Human platelet heparanase: purification, characterization and catalytic activity. Biochem J. 1998;330:1341–1350
  8. Pikas DS, Li JP, Vlodavsky I, et al. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem. 1998;273:18770–18777
  9. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta. 2001;1471:M99–M108
  10. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 2001;108:341–347
  11. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci. 2000;25:349–351
  12. Hulett MD, Freeman C, Hamdorf BJ, et al. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med. 1999;5:803–809
  13. Kussie PH, Hulmes JD, Ludwig DL, et al. Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun. 1999;261:183–187
  14. Toyoshima M, Nakajima M. Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem. 1999;274:24153–24160
  15. Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med. 1999;5:793–802
  16. Goldshmidt O, Zcharia E, Aingorn H, et al. Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence. J Biol Chem. 2001;276:29178–29187
  17. Labarrere CA, Pitts D, Halbrook H, et al. Natural anticoagulant pathways in normal and transplanted human hearts. J Heart Lung Transplant. 1992;11:342–347
  18. de Agostini AI, Watkins SC, Slayter HS, et al. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol. 1990;111:1293–1304
  19. Girardin EP, Hajmohammadi S, Birmele B, et al. Synthesis of anticoagulantly active heparan sulfate proteoglycans by glomerular epithelial cells involves multiple 3-O-sulfotransferase isoforms and a limiting precursor pool. J Biol Chem. 2005;280:38059–38070
  20. Sarafanov AG, Ananyeva NM, Shima M, et al. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem. 2001;276:11970–11979
  21. Ho G, Broze GJ, Schwartz AL. Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes. J Biol Chem. 1997;272:16838–16844
  22. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev. 2005;6:646–656
  23. Parish CR, Coombe DR, Jakobsen KB, et al. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases. Int J Cancer. 1987;40:511–518
  24. Bar-Ner M, Eldor A, Wasserman L, et al. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood. 1987;70:551–557
  25. Naggi A, Casu B, Perez M, et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem. 2005;280:12103–12113
  26. Katz BZ, Muhl L, Zwang E, et al. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms. Thromb Haemost. 2007;98:1193–1199
  27. Nadir Y, Brenner B, Zetser A, et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost. 2006;4:2443–2451
  28. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006;38:2018–2039
  29. Gingis-Velitski S, Zetser A, Flugelman MY, et al. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem. 2004;279:23536–23541
  30. Zetser A, Bashenko Y, Edovitsky E, et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 2006;66:1455–1463
  31. Kamikura Y, Wada H, Yamada A, et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol. 1997;55:183–187
  32. Misumi K, Ogawa H, Yasue H, et al. Circadian variation in plasma levels of free-form tissue factor pathway inhibitor antigen in patients with coronary spastic angina. Jpn Circ J. 1998;62:419–424
  33. Yamamuro M, Wada H, Kumeda K, et al. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 1998;9:491–497
  34. Leurs PB, Stolk RP, Hamulyak K, et al. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2002;25:1340–1345
  35. Al-Mugeiren MM, Abdel Gader AG, Al-Rasheed SA, et al. Tissue factor pathway inhibitor in childhood nephrotic syndrome. Pediatr Nephrol. 2006;21:771–777
  36. Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol. 1998;102:889–895
  37. Iversen N, Lindahl AK, Abildgaard U. Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. Thromb Res. 2002;105:33–36
  38. Shafat I, Zcharia E, Nisman B, et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun. 2006;341:958–963
  39. Vlodavsky I, Eldor A, Haimovitz-Friedman A, et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis. 1992;12:112–127
  40. Vlodavsky I, Abboud-Jarrous G, Elkin M, et al. The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb. 2006;35:116–127
  41. Bar-Sela G, Kaplan-Cohen V, Ilan N, et al. Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. Histopathology. 2006;49:188–193
  42. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol. 2005;25:1545–1550
  43. Elkin M, Ilan N, Ishai-Michaeli R, et al. Heparanase as mediator of angiogenesis: mode of action. Faseb J. 2001;15:1661–1663
  44. Friedmann Y, Vlodavsky I, Aingorn H, et al. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol. 2000;157:1167–1175
  45. Folkman J, Klagsbrun M, Sasse J, et al. A heparin-binding angiogenic protein – basic fibroblast growth factor – is stored within basement membrane. Am J Pathol. 1988;130:393–400
  46. Vlodavsky I, Miao HQ, Medalion B, et al. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev. 1996;15:177–186
  47. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, et al. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?. Trends Biochem Sci. 1991;16:268–271
  48. Sato T, Yamaguchi A, Goi T, et al. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol. 2004;87:174–181
  49. Xu X, Quiros RM, Maxhimer JB, et al. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res. 2003;9:5968–5979
  50. El-Assal ON, Yamanoi A, Ono T, et al. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res. 2001;7:1299–1305
  51. Kim AW, Xu X, Hollinger EF, et al. Human heparanase-1 gene expression in pancreatic adenocarcinoma. J Gastrointest Surg. 2002;6:167–172
  52. Rohloff J, Zinke J, Schoppmeyer K, et al. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer. 2002;86:1270–1275
  53. Gohji K, Okamoto M, Kitazawa S, et al. Heparanase protein and gene expression in bladder cancer. J Urol. 2001;166:1286–1290
  54. Gohji K, Hirano H, Okamoto M, et al. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer. 2001;95:295–301
  55. Shinyo Y, Kodama J, Hongo A, et al. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol. 2003;14:1505–1510
  56. Maxhimer JB, Quiros RM, Stewart R, et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery. 2002;132:326–333
  57. Takaoka M, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest. 2003;83:613–622
  58. Tang W, Nakamura Y, Tsujimoto M, et al. Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol. 2002;15:593–598
  59. Ogishima T, Shiina H, Breault JE, et al. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res. 2005;11:1028–1036
  60. Beckhove P, Helmke BM, Ziouta Y, et al. Heparanase expression at the invasion front of human head and neck cancers and correlation with poor prognosis. Clin Cancer Res. 2005;11:2899–2906
  61. Mikami S, Ohashi K, Usui Y, et al. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res. 2001;92:1062–1073
  62. Kelly T, Miao HQ, Yang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res. 2003;63:8749–8756
  63. Bitan M, Polliack A, Zecchina G, et al. Heparanase expression in human leukemias is restricted to acute myeloid leukemias. Exp Hematol. 2002;30:34–41
  64. Schubert SY, Ilan N, Shushy M, et al. Human heparanase nuclear localization and enzymatic activity. Lab Invest. 2004;84:535–544
  65. Ohkawa T, Naomoto Y, Takaoka M, et al. Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab Invest. 2004;84:1289–1304
  66. Doweck I, Kaplan-Cohen V, Naroditsky I, et al. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia. 2006;8:1055–1061
  67. Nadir Y, Brenner B, Gingis-Velitski S, et al. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Throm Haemost. 2008;99:133–141

PII: S1521-6926(08)00109-6

doi: 10.1016/j.beha.2008.12.004

Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 85-92 , March 2009

Article Tools

* Image Usage & Resolution